{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:46:20Z","timestamp":1789238780253,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"publisher","award":["51327"],"award-info":[{"award-number":["51327"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2026.01.018","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:51:48Z","timestamp":1768776708000},"page":"553.e1-553.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biogenic Selenium Nanoparticles Potentiate Anti-Mesothelin CAR-T Cell Therapy in a Syngeneic TNBC Model"],"prefix":"10.1016","volume":"32","author":[{"given":"Mina","family":"Hosseini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Shahosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0929-4880","authenticated-orcid":false,"given":"Ahmad Reza Panahi","family":"Meymandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-372X","authenticated-orcid":false,"given":"Ahmad Reza","family":"Shahverdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Faramarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Ghassemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8747-123X","authenticated-orcid":false,"given":"Jamshid","family":"Hadjati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8567-8555","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Yazdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3303-2565","authenticated-orcid":false,"given":"Hamid Reza","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtct.2026.01.018_bib0001","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"issue":"6382","key":"10.1016\/j.jtct.2026.01.018_bib0002","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jtct.2026.01.018_bib0003","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2026.01.018_bib0004","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"7949","key":"10.1016\/j.jtct.2026.01.018_bib0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.jtct.2026.01.018_bib0006","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.018_bib0007","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2026.01.018_bib0008","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/biomedicines10030655","article-title":"Assessing the future of solid tumor immunotherapy","volume":"10","author":"Guha","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jtct.2026.01.018_bib0009","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.3390\/ijms26072923","article-title":"Immune modulation and immunotherapy in solid tumors: mechanisms of resistance and potential therapeutic strategies","volume":"26","author":"Giri","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"22","key":"10.1016\/j.jtct.2026.01.018_bib0010","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.3390\/cells11223626","article-title":"Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.018_bib0011","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.018_bib0012","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-024-03648-y","article-title":"Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma","volume":"73","author":"Dai","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/j.jtct.2026.01.018_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013518","article-title":"Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery","volume":"13","author":"Stewart","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2026.01.018_bib0014","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.mattod.2017.11.022","article-title":"Metallic nanoparticles for cancer immunotherapy","volume":"21","author":"Evans","year":"2018","journal-title":"Mater Today (Kidlington)"},{"issue":"21","key":"10.1016\/j.jtct.2026.01.018_bib0015","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.3390\/cancers13215335","article-title":"Anticancer activity of biogenic selenium nanoparticles: apoptotic and immunogenic cell death markers in colon cancer cells","volume":"13","author":"Spyridopoulou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2026.01.018_bib0016","article-title":"Immunomodulatory roles of selenium nanoparticles: novel arts for potential immunotherapy strategy development","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.01.018_bib0017","article-title":"Recent research progress on the synthesis and biological effects of selenium nanoparticles","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Nutr"},{"key":"10.1016\/j.jtct.2026.01.018_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119397","article-title":"Selenium nanoparticles as new strategy to potentiate \u03b3\u03b4 T cell anti-tumor cytotoxicity through upregulation of tubulin-\u03b1 acetylation","volume":"222","author":"Hu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jtct.2026.01.018_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100975","article-title":"Selenium nanoparticles regulates selenoprotein to boost cytokine-induced killer cells-based cancer immunotherapy","volume":"35","author":"Liu","year":"2020","journal-title":"Nano Today"},{"key":"10.1016\/j.jtct.2026.01.018_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121321","article-title":"Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy","volume":"280","author":"Pan","year":"2022","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.jtct.2026.01.018_bib0021","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.7150\/ijbs.95484","article-title":"Seleno-amino acid metabolism reshapes the tumor microenvironment: from cytotoxicity to immunotherapy","volume":"20","author":"Liang","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10.1016\/j.jtct.2026.01.018_bib0022","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10549-012-2018-4","article-title":"Mesothelin, a novel immunotherapy target for triple negative breast cancer","volume":"133","author":"Tchou","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jtct.2026.01.018_bib0023","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3389\/fonc.2020.01195","article-title":"Multi-omics characterization of the 4T1 murine mammary gland tumor model","volume":"10","author":"Schr\u00f6rs","year":"2020","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.01.018_bib0024","doi-asserted-by":"crossref","first-page":"e1107","DOI":"10.1002\/cpz1.1107","article-title":"Generation of murine chimeric antigen receptor-modified T cells for in vivo studies in syngeneic tumor models","volume":"4","author":"Hosseini","year":"2024","journal-title":"Curr Protoc"},{"issue":"12","key":"10.1016\/j.jtct.2026.01.018_bib0025","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.4049\/jimmunol.159.12.5921","article-title":"Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells","volume":"159","author":"Levine","year":"1997","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.018_bib0026","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.01.018_bib0027","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","article-title":"A comprehensive immunologic portrait of triple-negative breast cancer","volume":"11","author":"Liu","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jtct.2026.01.018_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.018_bib0029","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.01.018_bib0030","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted CAR-T cell therapy for solid tumors","volume":"21","author":"Klampatsa","year":"2021","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.01.018_bib0031","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1007\/s12011-023-04042-y","article-title":"Biogenic selenium nanoparticles synthesized by L. brevis 23017 enhance aluminum adjuvanticity and make up for its disadvantage in mice","volume":"202","author":"Zhang","year":"2024","journal-title":"Biol Trace Elem Res"},{"issue":"6","key":"10.1016\/j.jtct.2026.01.018_bib0032","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1751-7915.12374","article-title":"Biogenic selenium nanoparticles: characterization, antimicrobial activity and effects on human dendritic cells and fibroblasts","volume":"9","author":"Cremonini","year":"2016","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.jtct.2026.01.018_bib0033","series-title":"A Study to Evaluate the Efficiency of Selenium Nanoparticles (SeNPs) to Overcome the Immunosuppressive Condition of the Tumor Microenvironment (TME) in the 4T1 Breast Cancer Model","author":"Hossein-Zadeh","year":"2023"},{"issue":"7637","key":"10.1016\/j.jtct.2026.01.018_bib0034","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2026.01.018_bib0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cyto.2016.11.005","article-title":"Combined effect of aerobic interval training and selenium nanoparticles on expression of IL-15 and IL-10\/TNF-\u03b1 ratio in skeletal muscle of 4T1 breast cancer mice with cachexia","volume":"90","author":"Molanouri Shamsi","year":"2017","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.018_bib0036","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12951-017-0276-3","article-title":"Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation","volume":"15","author":"Sonkusre","year":"2017","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.018_bib0037","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1038\/s41467-023-40087-2","article-title":"Structures of p53\/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity","volume":"14","author":"Wei","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jtct.2026.01.018_bib0038","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12011-012-9402-0","article-title":"The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: an in vivo study","volume":"149","author":"Yazdi","year":"2012","journal-title":"Biol Trace Elem Res"},{"key":"10.1016\/j.jtct.2026.01.018_bib0039","article-title":"Anti-breast cancer activity of biosynthesized selenium nanoparticles using Bacillus coagulans supernatant","volume":"82","author":"Khaledizade","year":"2024","journal-title":"J Trace Elem Med Biol"},{"key":"10.1016\/j.jtct.2026.01.018_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.600659","article-title":"Nanoparticles for enhanced adoptive T cell therapies and future perspectives for CNS tumors","volume":"12","author":"Balakrishnan","year":"2021","journal-title":"Front Immunol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:07:27Z","timestamp":1780312047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666636726000527"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.018","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biogenic Selenium Nanoparticles Potentiate Anti-Mesothelin CAR-T Cell Therapy in a Syngeneic TNBC Model","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}